{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T03:29:27Z","timestamp":1783913367062,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T00:00:00Z","timestamp":1294876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s10096-010-1140-7","type":"journal-article","created":{"date-parts":[[2011,1,12]],"date-time":"2011-01-12T11:07:21Z","timestamp":1294830441000},"page":"677-683","source":"Crossref","is-referenced-by-count":35,"title":["Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem?"],"prefix":"10.1007","volume":"30","author":[{"given":"J.","family":"Kehrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kaase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Szabados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. G.","family":"Gatermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Buer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-M.","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,13]]},"reference":[{"key":"1140_CR1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.diagmicrobio.2004.05.003","volume":"50","author":"DJ Biedenbach","year":"2004","unstructured":"Biedenbach DJ, Moet GJ, Jones RN (2004) Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997\u20132002). Diagn Microbiol Infect Dis 50:59\u201369","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1140_CR2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1086\/313650","volume":"30","author":"A Soriano","year":"2000","unstructured":"Soriano A, Martinez JA, Mensa J, Marco F, Almela M, Moreno-Martinez A, S\u00e1nchez F, Mu\u00f1oz I, Jim\u00e9nez de Anta MT, Soriano E (2000) Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 30:368\u2013373","journal-title":"Clin Infect Dis"},{"key":"1140_CR3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.118.1.146","volume":"118","author":"EH Ibrahim","year":"2000","unstructured":"Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146\u2013155","journal-title":"Chest"},{"key":"1140_CR4","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","volume":"34","author":"A Kumar","year":"2006","unstructured":"Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589\u20131596","journal-title":"Crit Care Med"},{"key":"1140_CR5","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3201\/eid1111.050524","volume":"11","author":"EW Tiemersma","year":"2005","unstructured":"Tiemersma EW, Monnet DL, Bruinsma N, Skov R, Monen JC, Grundmann H (2005) Staphylococcus aureus bacteremia, Europe. Emerg Infect Dis 11:1798\u20131799","journal-title":"Emerg Infect Dis"},{"key":"1140_CR6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","volume":"36","author":"SE Cosgrove","year":"2003","unstructured":"Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36:53\u201359","journal-title":"Clin Infect Dis"},{"key":"1140_CR7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5694\/j.1326-5377.2001.tb143562.x","volume":"175","author":"M Whitby","year":"2001","unstructured":"Whitby M, McLaws ML, Berry G (2001) Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 175:264\u2013267","journal-title":"Med J Aust"},{"key":"1140_CR8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-0711-5-2","volume":"5","author":"D Styers","year":"2006","unstructured":"Styers D, Sheehan DJ, Hogan P, Sahm DF (2006) Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 5:2","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"1140_CR9","unstructured":"Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA (2009) F\u00fcr die Studiengruppe. Resistenzsituation bei klinisch wichtigen Infektionserregern gegen\u00fcber Antibiotika in Deutschland und im mitteleurop\u00e4ischen Raum. Bericht \u00fcber die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitspr\u00fcfungen & Resistenz der Paul-Ehrlich-Gesellschaft f\u00fcr Chemotherapie e.V. aus dem Jahre 2007. Antiinfective Intelligence, Rheinbach"},{"key":"1140_CR10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/40.1.135","volume":"40","author":"K Hiramatsu","year":"1997","unstructured":"Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135\u2013136","journal-title":"J Antimicrob Chemother"},{"key":"1140_CR11","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/JCM.36.4.1020-1027.1998","volume":"36","author":"FC Tenover","year":"1998","unstructured":"Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, O'Hara CM, McAllister SK, Clark NC, Hiramatsu K (1998) Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 36:1020\u20131027","journal-title":"J Clin Microbiol"},{"key":"1140_CR12","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1128\/JCM.41.6.2487-2491.2003","volume":"41","author":"A Griethuysen Van","year":"2003","unstructured":"Van Griethuysen A, Van 't Veen A, Buiting A, Walsh T, Kluytmans J (2003) High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands. J Clin Microbiol 41:2487\u20132491","journal-title":"J Clin Microbiol"},{"issue":"Suppl 1","key":"1140_CR13","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0924-8579(00)00303-4","volume":"16","author":"PA Moise","year":"2000","unstructured":"Moise PA, Schentag JJ (2000) Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 16(Suppl 1):S31\u2013S34","journal-title":"Int J Antimicrob Agents"},{"key":"1140_CR14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","volume":"46","author":"A Soriano","year":"2008","unstructured":"Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J (2008) Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46:193\u2013200","journal-title":"Clin Infect Dis"},{"key":"1140_CR15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/381202","volume":"38","author":"BP Howden","year":"2004","unstructured":"Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML (2004) Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38:521\u2013528","journal-title":"Clin Infect Dis"},{"key":"1140_CR16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/381093","volume":"38","author":"PG Charles","year":"2004","unstructured":"Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML (2004) Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38:448\u2013451","journal-title":"Clin Infect Dis"},{"key":"1140_CR17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1471-2334-10-159","volume":"10","author":"JL Wang","year":"2010","unstructured":"Wang JL, Wang JT, Sheng WH, Chen YC, Chang SC (2010) Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC\u2009=\u20092\u00a0mg\/L, by the broth microdilution method. BMC Infect Dis 10:159","journal-title":"BMC Infect Dis"},{"key":"1140_CR18","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","volume":"60","author":"G Steinkraus","year":"2007","unstructured":"Steinkraus G, White R, Friedrich L (2007) Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001\u201305. J Antimicrob Chemother 60:788\u2013794","journal-title":"J Antimicrob Chemother"},{"key":"1140_CR19","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1128\/JCM.01388-06","volume":"44","author":"G Wang","year":"2006","unstructured":"Wang G, Hindler JF, Ward KW, Bruckner DA (2006) Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44:3883\u20133886","journal-title":"J Clin Microbiol"},{"key":"1140_CR20","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.00582-08","volume":"46","author":"MJ Rybak","year":"2008","unstructured":"Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN (2008) Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 46:2950\u20132954","journal-title":"J Clin Microbiol"},{"key":"1140_CR21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jinf.2009.11.011","volume":"60","author":"PL Ho","year":"2010","unstructured":"Ho PL, Lo PY, Chow KH, Lau EH, Lai EL, Cheng VC, Kao RY (2010) Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect 60:140\u2013145","journal-title":"J Infect"},{"key":"1140_CR22","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1128\/AAC.00616-09","volume":"53","author":"HS Sader","year":"2009","unstructured":"Sader HS, Fey PD, Limaye AP, Madinger N, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K, Jones RN (2009) Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 53:4127\u20134132","journal-title":"Antimicrob Agents Chemother"},{"key":"1140_CR23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/jac\/dkn246","volume":"62","author":"JI Al\u00f3s","year":"2008","unstructured":"Al\u00f3s JI, Garcia-Ca\u00f1as A, Garcia-Hierro P, Rodriguez-Salvan\u00e9s F (2008) Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother 62:773\u2013775","journal-title":"J Antimicrob Chemother"},{"key":"1140_CR24","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/513203","volume":"44","author":"FC Tenover","year":"2007","unstructured":"Tenover FC, Moellering RC Jr (2007) The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44:1208\u20131215","journal-title":"Clin Infect Dis"},{"key":"1140_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2007.03.006","volume":"30","author":"IM Gould","year":"2007","unstructured":"Gould IM (2007) The problem with glycopeptides. Int J Antimicrob Agents 30:1\u20133","journal-title":"Int J Antimicrob Agents"},{"key":"1140_CR26","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52:3315\u20133320","journal-title":"Antimicrob Agents Chemother"},{"key":"1140_CR27","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","volume":"42","author":"G Sakoulas","year":"2004","unstructured":"Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398\u20132402","journal-title":"J Clin Microbiol"},{"issue":"Suppl 1","key":"1140_CR28","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1086\/491710","volume":"42","author":"RN Jones","year":"2006","unstructured":"Jones RN (2006) Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal\/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 42(Suppl 1):S13\u2013S24","journal-title":"Clin Infect Dis"},{"key":"1140_CR29","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1128\/AAC.00904-08","volume":"52","author":"V Prakash","year":"2008","unstructured":"Prakash V, Lewis JS 2nd, Jorgensen JH (2008) Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 52:4528","journal-title":"Antimicrob Agents Chemother"},{"key":"1140_CR30","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijantimicag.2008.05.007","volume":"32","author":"DI Hsu","year":"2008","unstructured":"Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A (2008) Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 32:378\u2013385","journal-title":"Int J Antimicrob Agents"},{"key":"1140_CR31","doi-asserted-by":"crossref","first-page":"e1000215","DOI":"10.1371\/journal.pmed.1000215","volume":"7","author":"H Grundmann","year":"2010","unstructured":"Grundmann H, Aanensen DM, van den Wijngaard CC, Spratt BG, Harmsen D, Friedrich AW, European Staphylococcal Reference Laboratory Working Group (2010) Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis. PLoS Med 7:e1000215","journal-title":"PLoS Med"},{"key":"1140_CR32","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jac\/dkn329","volume":"62","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Miller CD, Graves J, Evans A, Graffunder E, Helmecke M, Stellrecht K (2008) Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 62:1138\u20131141","journal-title":"J Antimicrob Chemother"},{"key":"1140_CR33","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","volume":"166","author":"LK Hidayat","year":"2006","unstructured":"Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166:2138\u20132144","journal-title":"Arch Intern Med"},{"key":"1140_CR34","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","volume":"48","author":"KL LaPlante","year":"2004","unstructured":"LaPlante KL, Rybak MJ (2004) Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48:4665\u20134672","journal-title":"Antimicrob Agents Chemother"},{"key":"1140_CR35","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.amjmed.2007.07.012","volume":"120","author":"G Sakoulas","year":"2007","unstructured":"Sakoulas G, Golan Y, Lamp KC, Friedrich LV, Russo R (2007) Daptomycin in the treatment of bacteremia. Am J Med 120:S21\u2013S27","journal-title":"Am J Med"},{"key":"1140_CR36","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1378\/chest.124.5.1789","volume":"124","author":"RG Wunderink","year":"2003","unstructured":"Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH (2003) Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789\u20131797","journal-title":"Chest"},{"key":"1140_CR37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler Jr","year":"2006","unstructured":"Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE, S. aureus Endocarditis and Bacteremia Study Group (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653\u2013665","journal-title":"N Engl J Med"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-010-1140-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-010-1140-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-010-1140-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T13:57:28Z","timestamp":1592229448000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-010-1140-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,13]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1007\/s10096-010-1140-7","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,13]]}}}